Use of the quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patients.
The potential use of the quinolones in the prophylaxis and treatment of febrile episodes in granulocytopenic patients is reviewed. Of 7 controlled prophylactic studies performed with quinolones, 2 were double-blind and placebo-controlled. The occurrence of fever and mortality due to infection was not reduced with quinolone prophylaxis, although the occurrence of Gram-negative bacteraemia was significantly reduced. The delay to first fever was occasionally increased, and this was associated with a reduction in the number of days with antimicrobial agents. No effect was observed on disseminated fungal infections with quinolone prophylaxis. Breakthrough bacteraemia and subsequent infections were due to resistant organisms, mainly Gram-positive organisms (streptococci, staphylococci). Tolerability and compliance were excellent and were occasionally better than with the classic regimen [nonabsorbable antibiotics and cotrimoxazole (trimethoprim/sulfamethoxazole)]. Six controlled studies dealing with empiric treatment with the quinolones were reviewed. Overall, the results suggested that monotherapy with ciprofloxacin may be used in patients with a good prognosis (short and less severe neutropenia, solid tumours, compliant patients). Combinations with broad spectrum penicillins, netilmicin or teicoplanin seem to be as effective as the classic regimens (a broad spectrum penicillin or cephalosporin plus aminoglycosides), although the number of patients was limited (n = 334). The response rate of Gram-positive bacteraemia was lower with quinolone-containing regimens except for a combination that included teicoplanin.
Van der Auwera
P
P
Clinique des Maladies Infectieuses, Institut Jules Bordet, Université Libre de Bruxelles, Belgium.
Gérain
J
J
D000284:Administration, Oral; D000380:Agranulocytosis / Q000188:drug therapy* / Q000276:immunology* / Q000517:prevention & control; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D024841:Fluoroquinolones; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects; D007938:Leukemia / Q000150:complications*; D009503:Neutropenia / Q000150:complications; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic
D000890:Anti-Infective Agents; D024841:Fluoroquinolones